CB21 Pharma s.r.o.

CB21 Pharma s.r.o. is a Czech pharmaceutical and cosmetic company founded in 2018 that develops medical therapies and functional solutions using non-psychotropic cannabinoids like CBD and Dronabinol. The firm leverages evidence-based research to address unmet needs in gynaecology, urology, proctology, dentistry, and psychiatry while maintaining a commitment to environmental responsibility through sustainable manufacturing practices.

• Products: Offers CE-certified medical devices including CANNEFF® SUP and VAG SUP suppositories alongside refined cannabis extracts and Dronabinol for chronic pain and epilepsy management.
• Certifications: Holds EU GMP Part II certification for API cannabidiol manufacture, ISO 13485 compliance, and specific CE marks for gynaecological and proctological applications.
• Innovation: Utilizes a data-driven approach combining preclinical evaluations with clinical trials to validate the therapeutic efficacy of phytocannabinoids across various receptor interactions.

The company collaborates closely with scientific experts from Palacký University Olomouc and Masaryk University Brno to advance treatment standards for prevalent conditions where current therapies are limited.